Recursion Pharmaceuticals and Exscientia announce merger to transform drug development
Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have announced a landmark merger, combining their strengths to form a formidable entity in drug ... Read More
Alliqua BioMedical to acquire Adynxx, forming new clinical-stage pharmaceutical leader
Pennsylvania-based Alliqua BioMedical has announced a significant merger with San Francisco's Adynxx, aiming to establish a clinical-stage pharmaceutical entity dedicated to non-opioid pain management therapies. ... Read More
Takeda Pharmaceutical proposes $62bn acquisition of Shire to expand rare disease capabilities
Takeda Pharmaceutical, a major Japanese pharmaceutical company, has made a $62 billion offer to acquire Shire, an Ireland-based leader in rare disease treatments. This proposal, ... Read More